search
Back to results

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography (GE OCT)

Primary Purpose

Coronary Artery Disease, Contrast Media Reaction

Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Iodixanol
Iohexol
Sponsored by
Minneapolis Heart Institute Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Coronary Artery Disease focused on measuring Optical Coherence Tomography, Contrast Agents

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years or greater
  2. Willing and able to give informed consent. The patients must be able to comply with study procedures
  3. Undergoing clinically-indicated coronary angiography and OCT

Exclusion Criteria

  1. Baseline electrocardiographic changes hindering interpretation (such as left bundle-branch block, and >1 mm ST segment depression)
  2. Emergency cardiac catheterization (for example in patients with ST-segment elevation acute myocardial infarction)
  3. Inability to provide symptomatic assessment
  4. Known allergy to contrast

Sites / Locations

  • Minneapolis Heart Institute FoundationRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Iso-Osmolar Contrast Media

Low-Osmolar Contrast Media

Arm Description

Will receive iso-osmolar media first, low-osmolar media second

Will receive low-osmolar media first, iso-osmolar media second

Outcomes

Primary Outcome Measures

Contrast Volume after Injection
Contrast volume will be measured after each injection

Secondary Outcome Measures

Clear OCT Images
Length of clear OCT images will be defined as visible lumen border >270 degrees
Electrocardiographic (ECG) Changes
Electrocardiographic(ECG) changes will be assessed during and for a period of 30 seconds after each injection of contrast for OCT, to detect and quantify any of the following abnormalities: arrhythmias, mean axis deviation and QRS enlargement (type A abnormalities); and ventricular repolarization (ST/T) changes (type B abnormalities)

Full Information

First Posted
September 14, 2021
Last Updated
October 19, 2021
Sponsor
Minneapolis Heart Institute Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05065073
Brief Title
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
Acronym
GE OCT
Official Title
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 30, 2021 (Actual)
Primary Completion Date
March 31, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Minneapolis Heart Institute Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed study aims to compare (a) volume contrast administered for Optical Coherence Tomography (OCT) Imaging, (b) length of clear OCT images, and (c) electrocardiographic changes immediately after contrast injection between iso-osmolar and low-osmolar contrast agents. The proposed study is a prospective, single-centered, randomized controlled, study that will compare an iso-osmolar vs. a low-osmolar contrast agent in patients undergoing clinically indicated coronary OCT imaging. Each patient will be randomized to OCT acquisition.
Detailed Description
Patients referred to the Cardiac Catheterization laboratory for clinically indicated coronary angiography and coronary OCT imaging will be identified by a study team member and screened for eligibility. The proposed study is a prospective, single-center, randomized, controlled, study that will compare an iso-osmolar vs a low-osmolar contrast agent in patients undergoing clinically-indicated coronary OCT imaging. Each patient will be randomized to OCT acquisition. Eligible patients will be approached to obtain informed consent by a member of the study team. Once consent is obtained and inclusion and exclusion criteria are verified, patients are randomized to undergoing OCT image acquisition with iso-osmolar contrast media(IOCM) first or with low-osmolar contrast media first (LOCM). Then the patients undergo coronary angiography and OCT imaging as per clinical standard of care. However, during the OCT imaging acquisition based on their randomization assignment the patient will undergo the 1st OCT imaging run with either iso-osmolar contrast media or with low-osmolar contrast media. Following this a 2nd OCT imaging run of the same coronary vessel will be done using the other contrast media that was not used during the first run. Therefore, each patient will serve as a comparator to themselves, but also to each other. The electrocardiogram will be recorded during and for 30 seconds after each injection and analyzed offline for detection of any changes

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Contrast Media Reaction
Keywords
Optical Coherence Tomography, Contrast Agents

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
Randomized, controlled study. Each patient will be randomized to undergoing OCT image acquisition with iso-osmolar contrast media first, or with low-osmolar contrast media first. Following this will be a second OCT image acquisition of the same coronary vessel with the other contrast media. Thus, each patient will serve as comparator to themselves, and to each other
Masking
None (Open Label)
Allocation
Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Iso-Osmolar Contrast Media
Arm Type
Active Comparator
Arm Description
Will receive iso-osmolar media first, low-osmolar media second
Arm Title
Low-Osmolar Contrast Media
Arm Type
Active Comparator
Arm Description
Will receive low-osmolar media first, iso-osmolar media second
Intervention Type
Drug
Intervention Name(s)
Iodixanol
Other Intervention Name(s)
Visipaque
Intervention Description
Iso-osmolar Contrast Media
Intervention Type
Drug
Intervention Name(s)
Iohexol
Other Intervention Name(s)
Omnipaque
Intervention Description
Low-Osmolar Contrast Media
Primary Outcome Measure Information:
Title
Contrast Volume after Injection
Description
Contrast volume will be measured after each injection
Time Frame
30 seconds after injection
Secondary Outcome Measure Information:
Title
Clear OCT Images
Description
Length of clear OCT images will be defined as visible lumen border >270 degrees
Time Frame
Intra-operative
Title
Electrocardiographic (ECG) Changes
Description
Electrocardiographic(ECG) changes will be assessed during and for a period of 30 seconds after each injection of contrast for OCT, to detect and quantify any of the following abnormalities: arrhythmias, mean axis deviation and QRS enlargement (type A abnormalities); and ventricular repolarization (ST/T) changes (type B abnormalities)
Time Frame
During and 30 seconds after injection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or greater Willing and able to give informed consent. The patients must be able to comply with study procedures Undergoing clinically-indicated coronary angiography and OCT Exclusion Criteria Baseline electrocardiographic changes hindering interpretation (such as left bundle-branch block, and >1 mm ST segment depression) Emergency cardiac catheterization (for example in patients with ST-segment elevation acute myocardial infarction) Inability to provide symptomatic assessment Known allergy to contrast
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bavana Rangan, BDS, MPH
Phone
817-821-9945
Email
bavana.rangan@allina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emmanouil Brilakis, MD, PhD
Organizational Affiliation
Minneapolis Heart Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Minneapolis Heart Institute Foundation
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bavana V Rangan, BDS, MPH
Phone
817-821-9945
Email
bavana.rangan@allina.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

We'll reach out to this number within 24 hrs